What's better than momentum? Mo' momentum.

Let's take a closer look at five of this past week's biggest scorchers.


Nov. 9

Weekly Gain

My Watchlist

BioMarin Pharmaceutical (NASDAQ:BMRN)




VirnetX Holding (NYSE:VHC)








Sequenom (NASDAQ: SQNM)




Smith & Wesson (NASDAQ:SWBI)




Source: Barron's.

BioMarin took some big steps forward as patients testing out its experimental drug did the same. In the treatment's critical phase 3 clinical trial, patients affected by Morquio A Syndrome had the ability to walk farther with the drug.

VirnetX was a stock market winner after winning in the courtroom. It was awarded a whopping $386.2 million in a patent infringement case against Apple.

Vringo is another company that came up big in its attempt to enforce its patents. Vringo's ruling against dot-com giants wasn't as lucrative as VirnetX's, but it's a welcome decision all the same.

VirnetX and Vringo may be patent trolls, but as of now they're wealthier patent trolls if they are able to collect on the damages.

Sequenom took off on a strong sales trend for its MaterniT21 test. Sequenom is handling roughly 1,700 of the tests, a blood test for pregnant women at high risk of delivering a Down syndrome baby. The trend indicates an annual run rate of 90,000 tests performed.

Shares of Smith & Wesson shot higher. Gun makers moved higher after Obama defeated Romney. It's a move that doesn't make a lot of sense. The fear is, naturally, that Obama will introduce stricter gun control laws. The move would generate a near-term run for weaponry, but what happens after that? It also bears pointing out that the stocks had a similar reaction four years ago -- and nothing materially changed.

More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers there's a special report on three companies ready to rule their industry. The report is free -- like this article -- but it won't be around forever, so click here to check it out now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.